Application of 3D Mass Spectrometry Imaging to TKIs
Clinical Pharmacology & Therapeutics2017Vol. 102(5), pp. 748–751
Citations Over TimeTop 11% of 2017 papers
Lavinia Morosi, Silvia Giordano, Francesca Falcetta, Roberta Frapolli, Simonetta Andrea Licandro, Cristina Matteo, Massimo Zucchetti, Paolo Ubezio, Eugenio Erba, Sonja Visentin, Maurizio D’Incalci, Enrico Davoli
Abstract
Mass spectrometry imaging (MSI) allows visualization of endogenous and exogenous compound in tissue sections based on its molecular mass. The 3D reconstruction by MSI provides a more informative description of the tumor drug distribution compared to the high-performance liquid chromatography method, highlighting the heterogeneity of intratumor drug concentration. This additional information can be important in understanding chemoresistance to target agents. Here, we present the 3D visualization of the tyrosine kinase inhibitor (TKI), imatinib, in a xenograft model of resistant malignant pleural mesothelioma.
Related Papers
- → Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells(2013)14 cited
- → Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era(2006)10 cited
- → Correlation of the c-kit mutational status of gastrointestinal stromal tumors with the clinical response to the tyrosine kinase inhibitor imatinib(2004)1 cited
- → Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinib(2006)
- → P722: IS THE SECOND-GENERATION TYROSINE KINASE INHIBITOR A BETTER THERAPY THAN IMATINIB FOR PERSONS WITH CHRONIC MYELOID LEUKEMIA PRESENTING IN ACCELERATED-PHASE?(2022)